Publications by authors named "M Pick"
Purpose: The use of anti-B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CART) therapy for AL amyloidosis (AL) is limited owing to patient frailty. HBI0101 anti-BCMA CART was the first proof of concept for its applicability to AL. This report addresses the AL patient cohort treated to date within the phase Ia/Ib clinical trial (ClinicalTrials.
View Article and Find Full Text PDFHBI0101 is an academic chimeric antigen receptor T-cell (CART)-targeted to B-cell maturation antigen (BCMA) for the treatment of relapsed and refractory multiple myeloma (R/RMM) and light chain amyloidosis. Herein, we present the phase 1b/2 results of 50 heavily pretreated patients with R/RMM dosed with 800 × 106 CART cells. Inclusion criteria were relatively permissive (i.
View Article and Find Full Text PDFSystemic light chain amyloidosis (AL) is a clonal plasma cell disorder characterized by the deposition of misfolded immunoglobulin light chains (LC) as insoluble fibrils in organs. The lack of suitable models has hindered the investigation of the disease mechanisms. Our aim was to establish AL LC-producing plasma cell lines and use them to investigate the biology of the amyloidogenic clone.
View Article and Find Full Text PDFArticle Synopsis
- Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR T) therapy, specifically the novel HBI0101, shows high effectiveness in treating heavily pre-treated patients with relapsed/refractory multiple myeloma (MM).
- A phase I study demonstrated a high overall response rate (75%), with a notable percentage achieving stringent complete responses (50%), while maintaining a manageable safety profile; most patients experienced mild cytokine release syndrome but no severe side effects.
- The results indicate promising efficacy, particularly at higher doses, and support the feasibility of producing CAR T cells in academic settings to meet growing patient needs.
Purpose: AL amyloidosis (AL) treatments are generally based on those employed for multiple myeloma. Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor T (CART)-cell therapy, already approved for multiple myeloma, might be too toxic for patients with AL.
Experimental Design: Here we describe the ex vivo applicability of a novel in-house, academic anti-BCMA CAR construct on AL primary cells, as well as the safety and efficacy in 4 patients with relapsed/refractory (RR) primary AL, treated in a phase I clinical trial (NCT04720313).